Osteoprotegerin/TNFRSF11B Antibody [Unconjugated]

Osteoprotegerin/TNFRSF11B was detected in immersion fixed paraffin-embedded sections of human lymph node using 15 µg/mL Goat Anti-Human Osteoprotegerin/TNFRSF11B Antigen Affinity-purified Polyclonal Antibody (Catalog # AF805) overnight at 4 °C. Tissue was stained with the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

Osteoprotegerin/TNFRSF11B was detected in immersion fixed paraffin-embedded sections of human lymph node using Goat Anti-Human Osteoprotegerin/TNFRSF11B Antigen Affinity-purified Polyclonal Antibody (Catalog # AF805) at 25 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). Specific labeling was localized to the cytoplasm and plasma membrane of lymphocytes. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

In the presence of a cross-linking antibody, Mouse polyHistidine Monoclonal Antibody (Catalog # MAB050) (Catalog # MAB050) and the metabolic inhibitor actinomycin D (1 µg/mL), Recombinant Human Osteoprotegerin/TNF­RSF11B (Catalog # 185-OS) inhibits Recombinant Human TRAIL/TNFSF10 (Catalog # 375‑TL) induced cytotoxicity in the L‑929 mouse fibroblast cell line in a dose-dependent manner (orange line), as measured by crystal violet staining. Under these conditions, inhibition of Recombinant Human TRAIL/TNFSF10 (20 ng/mL) activity elicited by Recombinant Human Osteoprotegerin/TNFRSF11B (0.1 µg/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human Osteoprotegerin/TNFRSF11B Antigen Affinity-purified Polyclonal Antibody (Catalog # AF805). The ND50 is typically 0.25-0.7 µg/mL.

• Reactivity: Hu
• Applications: WB, IHC, B/N
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated
• Concentration: LYOPH

Osteoprotegerin/TNFRSF11B Antibody [Unconjugated] Summary

• Immunogen: S. frugiperda insect ovarian cell line Sf 21-derived recombinant human Osteoprotegerin/TNFRSF11B
  Glu22-Leu401
  Accession # AAB53709
• Specificity: Detects human Osteoprotegerin/TNFRSF11B in direct ELISAs and Western blots. In direct ELISAs, approximately 20% cross-reactivity with recombinant mouse Osteoprotegerin is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: TNFRSF11B
• Purity Statement: Antigen Affinity-purified
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry 5-15 ug/mL
  • Neutralization 0.25-0.7 ug/mL
  • Western Blot 0.1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Osteoprotegerin/TNFRSF11B Antibody [Unconjugated]

• OCIF
• OCIFMGC29565
• OPG
• OPGtumor necrosis factor receptor superfamily member 11B
• Osteoclastogenesis inhibitory factor
• Osteoprotegerin
• TNFRSF11B
• TR1
• tumor necrosis factor receptor superfamily, member 11b

Background

Osteoprotegerin (OPG)/Osteoclastogenesis Inhibitory Factor (OCIF) is a member of the tumor necrosis factor receptor superfamily that lacks any apparent cell‑association motifs and exists as a soluble secreted protein. In the TNF superfamily nomenclature, OPG is referred to as TNFRSF11B. OPG was originally isolated by sequence homology as a TNF receptor family protein during a fetal rat intestine cDNA-sequencing project and subsequently shown to be involved in the regulation of bone density. OCIF was initially purified from the conditioned medium of human embryonic fibroblasts based on its ability to inhibit osteoclast development. Comparison of the amino acid (aa) sequences of human OPG and OCIF proteins revealed their identity. Human OPG/OCIF cDNA encodes a 401 aa residue precursor protein with a 21 aa residue putative signal peptide that is removed to generate the mature soluble protein. The amino-terminal half of OPG contains four cysteine-rich repeats characteristic of TNF receptor family members. The 204 residues of the carboxy-terminal OPG/OCIF was found to contain two death domain homologous regions in tandem. Human and mouse OPG share approximately 84% and 94% amino acid sequence identity, respectively, with the rat OPG. Natural OPG/OCIF has been found to exist predominantly as disulfide-linked dimers. Two TNF superfamily ligands, including the membrane proteins OPG ligand/TRANCE (tumor necrosis factor-related activation-induced cytokine)/ODF (osteoclast differentiation factor)/RANKL (receptor activator of NF kappa B ligand) and TRAIL (TNF-related apoptosis‑inducing ligand)/APO-2 ligand, have been shown to be the cellular ligands for OPG/OCIF. Each of these ligands has been shown to interact with additional TNF receptor family members, including RANK (with TRANCE) and TRAIL receptors 1 - 4 (with TRAIL). The roles of these receptor-ligands in osteoclastogenesis, apoptosis and in the immune system remains to be elucidated.

1. Lacey, D.L. et al. (1998) Cell 93:165.
2. Emery, J.G. et al. (1998) J. Biol. Chem. 273:14363.
3. Yasuda, H. et al. (1998) Proc. Natl. Acad. Sci. USA 95:3597.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for Osteoprotegerin/TNFRSF11B Antibody (AF805)(11)

Publications using AF805

• RM Samsonraj, SF Law, A Chandra, RJ Pignolo An unbiased proteomics approach to identify the senescence-associated secretory phenotype of human bone marrow-derived mesenchymal stem cells Bone Reports, 2023-03-21;18(0):101674. 2023-03-21 [PMID: 36994454] (Human)
• I Gomes, BP de Almeida, S Dâmaso, A Mansinho, I Correia, S Henriques, R Cruz-Duart, G Vilhais, P Félix, P Alves, P Corredeira, NL Barbosa-Mo, L Costa, S Casimiro Expression of receptor activator of NFkB (RANK) drives stemness and resistance to therapy in ER+HER2- breast cancer Oncotarget, 2020-05-12;11(19):1714-1728. 2020-05-12 [PMID: 32477461] (Western Blot, Human)
• Nagahiro Ochiai, Yutaka Nakachi, Tomotaka Yokoo, Takahiro Ichihara, Tore Eriksson, Yuki Yonemoto et al. Murine osteoclasts secrete serine protease HtrA1 capable of degrading osteoprotegerin in the bone microenvironment Communications Biology 2019-03-01 [PMID: 30854478]
• A Kapelouzou, C Kontogiann, DI Tsilimigra, G Georgiopou, L Kaklamanis, L Tsourelis, DV Cokkinos Differential expression patterns of Toll Like Receptors and Interleukin-37 between calcific aortic and mitral valve cusps in humans Cytokine, 2019-02-01;116(0):150-160. 2019-02-01 [PMID: 30716659] (IHC, Human)
• Sandy H. S. Hassan, Mahmoud I. El-Refai, Noha A. Ghallab, Rehab Fawzy Kasem, Olfat G. Shaker Effect of Periodontal Surgery on Osteoprotegerin Levels in Gingival Crevicular Fluid, Saliva, and Gingival Tissues of Chronic Periodontitis Patients Disease Markers 2015-02-28 [PMID: 25814780]
• Davaine J, Quillard T, Brion R, Laperine O, Guyomarch B, Merlini T, Chatelais M, Guilbaud F, Brennan M, Charrier C, Heymann D, Goueffic Y, Heymann M Osteoprotegerin, pericytes and bone-like vascular calcification are associated with carotid plaque stability. PLoS ONE, 2014-09-26;9(9):e107642. 2014-09-26 [PMID: 25259713] (IHC, Human)
• B. Essley, T. McNanley, B. Cooper, A. McIntyre, F. Witter, Z. Harris et al. Osteoprotegerin in pregnant adolescents differs by race and is related to infant birth weight z-score Journal of Developmental Origins of Health and Disease 2014-05-30 [PMID: 25141264]
• Akiyama T, Miyamoto Y, Yoshimura K, Yamada A, Takami M, Suzawa T, Hoshino M, Imamura T, Akiyama C, Yasuhara R, Mishima K, Maruyama T, Kohda C, Tanaka K, Potempa J, Yasuda H, Baba K, Kamijo R Porphyromonas gingivalis-derived lysine gingipain enhances osteoclast differentiation induced by tumor necrosis factor-alpha and interleukin-1beta but suppresses that by interleukin-17A: importance of proteolytic degradation of osteoprotegerin by lysine gingipain. J Biol Chem, 2014-04-22;289(22):15621-30. 2014-04-22 [PMID: 24755218] (Western Blot, Bacteria - Porphyromonas gingivalis)
• Chollet ME, Brouland JP, Bal dit Sollier C, Bauduer F, Drouet L, Bellucci S Evidence of a colocalisation of osteoprotegerin (OPG) with von Willebrand factor (VWF) in platelets and megakaryocytes alpha granules. Studies from normal and grey platelets. Br. J. Haematol., 2009-12-01;148(5):805-7. 2009-12-01 [PMID: 19958354] (Western Blot, Human)
• Cross SS, Yang Z, Brown NJ, Balasubramanian SP, Evans CA, Woodward JK, Neville-Webbe HL, Lippitt JM, Reed MW, Coleman RE, Holen I Osteoprotegerin (OPG)--a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis? Int. J. Cancer, 2006-04-15;118(8):1901-8. 2006-04-15 [PMID: 16287088] (Flow Cytometry, Human)
• Grimaud E, Soubigou L, Couillaud S, Coipeau P, Moreau A, Passuti N, Gouin F, Redini F, Heymann D Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am. J. Pathol., 2003-11-01;163(5):2021-31. 2003-11-01 [PMID: 14578201] (IHC-P, Human)

Bioinformatics

• Gene Symbol: TNFRSF11B
• Uniprot:
  • AAB53709()